Susquehanna International Group, LLP Arvinas, Inc. Put Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$23.66 - $32.73 $198,744 - $274,932	8,400 New	8,400 $206,000
Q1 2024 May 07, 2024	BUY	$36.38 - $52.31 $1.02 Million - $1.47 Million	28,100 Added 186.09%	43,200 $1.78 Million
Q4 2023 Feb 14, 2024	SELL	$14.19 - $42.33 $66,693 - $198,951	-4,700 Reduced 23.74%	15,100 $621,000
Q3 2023 Nov 14, 2023	SELL	$19.64 - $28.21 $428,152 - $614,978	-21,800 Reduced 52.4%	19,800 $388,000
Q2 2023 Aug 11, 2023	BUY	$21.73 - $31.43 $195,570 - $282,870	9,000 Added 27.61%	41,600 $1.03 Million
Q1 2023 May 16, 2023	SELL	$26.15 - $37.26 $2.57 Million - $3.66 Million	-98,100 Reduced 75.06%	32,600 $890,000
Q4 2022 Feb 14, 2023	BUY	$32.47 - $57.24 $1.93 Million - $3.39 Million	59,300 Added 83.05%	130,700 $4.47 Million
Q3 2022 Nov 14, 2022	BUY	$41.87 - $57.99 $2.74 Million - $3.79 Million	65,400 Added 1090.0%	71,400 $3.18 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.21B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.